Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313676 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 16,568
- Enrollment target
NCT01313676 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 16,568 participants.
The verdict
NCT01313676, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16,568 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
Interventions
- OTHER Placebo
- DRUG fluticasone furoate
- DRUG fluticasone furoate/vilanterol
- DRUG vilanterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16,568 participants |
| Start Date | 2011-01-25 |
| Est. Completion | 2015-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313676
The ClinicalTrials.gov registry entry for NCT01313676 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 16,568 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01313676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313676 about?
NCT01313676 is a clinical study titled "Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease". The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
What is the current status of trial NCT01313676?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16,568 participants. The study started on 2011-01-25. Estimated completion is 2015-07-15.
What interventions are being tested in trial NCT01313676?
The interventions under investigation include: Placebo (OTHER), fluticasone furoate (DRUG), fluticasone furoate/vilanterol (DRUG), vilanterol (DRUG).
Who is sponsoring clinical trial NCT01313676?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.